Unverified50% confidenceFactExact time
AML patients carrying FLT3 mutations can be treated with the targeted drugs midostaurin or gilteritinib, while patients with IDH1/2 mutations can use ivosidenib or enasidenib.
1
Sources
50%
Confidence
Long-term
Relevance
9/6/2026
First Seen
Sources
Related Entities
Cite This Claim
Stable URI
https://kongchang.com/claim/864683API
curl https://kongchang.com/api/v1/knowledge/claims/864683MCP
get_claim(id=864683)